Dabogratinib not checked

Tyra Biosciences, Inc · TYRA-300 · TYRA-300-B01

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total · 3 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.”In the company’s words, NCT06842355 on ClinicalTrials.gov
Tested for
FGFR3 Gene Alteration (2 trials), FGFR3 Gene Mutation (2 trials), Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Fusions, Achondroplasia, Low Grade Upper Tract Urothelial Carcinoma and 12 more
Main trialPhase 2
“Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC”In the company’s words, NCT06995677 on ClinicalTrials.gov
Other names
TYRA-300 · TYRA-300-B01

Other drugs for Achondroplasia

All 8 drugs for Achondroplasia

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Feb 2028 Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2Recruiting Jan 2030 A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Phase 2Recruiting Oct 2030 Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Phase 1/2Active, not recruiting Nov 2026 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Phase 1Active, not recruiting May 2025 A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Dabogratinib

Following is part of Solo: you see every change to Dabogratinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in